`
`Paper No. ___
`Filed: January 2, 2019
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
`INC. and AKORN INC.,1
`Petitioners,
`v.
`ALLERGAN, INC.,
`Patent Owner.
`
`_____________________________
`
`Case IPR2016-01127 (US 8,685,930 B2)
`Case IPR2016-01128 (US 8,629,111 B2)
`Case IPR2016-01129 (US 8,642,556 B2)
`Case IPR2016-01130 (US 8,633,162 B2)
`Case IPR2016-01131 (US 8,648,048 B2)
`Case IPR2016-01132 (US 9,248,191 B2)
`_____________________________
`
`PETITIONERS’ UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`1 Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596,
`IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599,
`IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601,
`have respectively been joined with the captioned proceedings. The word-for-word
`identical paper is filed in each proceeding identified in the caption pursuant to the
`Board’s Scheduling Order (Paper 10).
`
`
`
`
`
`
`
`LIST OF EXHIBITS
`
`Description
`
`The Patent (U.S. Patent No. 8,685,930; 8,629,111; 8,642,556;
`8,633,162; 8,648,048; or 9,248,191 to Acheampong et al., in
`IPR2016-01127 – IPR2016-01132, respectively)
`
`Declaration of Dr. Mansoor Amiji
`
`Curriculum Vitae of Dr. Mansoor Amiji
`
`File History (U.S. Patent No. 8,685,930; 8,629,111; 8,642,556;
`8,633,162; 8,648,048; or 9,248,191 to Acheampong et al., in
`IPR2016-01127 –01132, respectively)
`
`File history of U.S. Patent Application No. 10/927,857, filed on
`August 27, 2010 to Acheampong et al.
`
`Exhibit
`No.
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`U.S. Patent No. 5,474,979 to Ding et al., filed May 17, 1994
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`Sall, K., et al., Two Multicenter, Randomized Studies of the
`Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in
`Moderate to Severe Dry Eye Disease, 107 OPHTHALMOL. 631
`(2000)
`
`Acheampong, A., et al., Cyclosporine distribution into the
`conjunctiva, cornea, lacrimal gland, and systemic blood
`following topical dosing of cyclosporine to rabbit, dog, and
`human eyes, 2 LACRIMAL GLAND, TEAR FILM, AND DRY EYE
`SYNDROMES 1001 (1998)
`
`U.S. Patent No. 5,578,586 to Glonek et al., filed February 4, 1994
`
`U.S. Patent No. 5,981,607 to Ding et al., filed January 20, 1998
`
`Kaswan, R., Intraocular Penetration of Topically Applied
`Cyclosporine 20 TRANSPL. PROC. 650 (1988)
`
`
`
`
`
`-1-
`
`
`
`
`
`1012
`
`Kunert, K., et al., Analysis of Topical Cyclosporine Treatment of
`Patients with Dry Eye Syndrome 118 ARCH OPHTHALMOL 1489
`(2000)
`
`1013
`
`Physicians’ Desk Reference for Ophthalmic Medicines (1999)
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`Turner, K., et al., Interleukin-6 Levels in the Conjunctival
`Epithelium of Patients with Dry Eye Disease Treated with
`Cyclosporine Ophthalmic Emulsion 19 CORNEA 492 (2000)
`
`Stevenson, D., et al. Efficacy and Safety of Cyclosporin A
`Ophthalmic Emulsion in the Treatment of Moderate-to-Severe
`Dry Eye Disease 107 OPHTHALMOL. 967 (2000)
`Remington’s 20th Edition: The Science and Practice of Pharmacy
`(A. Gennaro ed. 2003)
`
`Goto, E., et al. Low-Concentration Homogenized Castor Oil Eye
`Drops for Noninflamed Obstructive Meibomian Gland
`Dysfunction 109 OPHTHALMOL. 2030 (2002)
`
`Kanpolat, A., et al., Penetration of Cyclosporin A into the Rabbit
`Cornea and Aqueous Humor after Topical Drop and Collagen
`Shield Administration 20 CLAO J. 119 (1994)
`
`1019
`
`Vieira, A., et al., Effect of ricinoleic acid in acute and subchronic
`experimental models of inflammation, 9 MED. INFLAMM. 223
`(2000)
`1020 Murphy, R., The Once and Future Treatment of Dry Eye, REVIEW
`OF OPTOMETRY 1 (2000)
`
`Small, D., et al., Blood concentrations of Cyclosporin A During
`Long-Term Treatment with Cyclosporin A Ophthalmic
`Emulsions in Patients with Moderate to Severe Dry Eye Disease
`18 J. OC. PHARM. THERAP. 411 (2002)
`Stedman’s Medical Dictionary 27th Edition (M.B. Pugh ed. 2000)
`
`1021
`
`1022
`
`-2-
`
`
`
`
`
`1023
`
`1024
`
`1025
`(IPR2016-
`01127)
`
`1025
`(IPR2016-
`01132)
`
`Complaint; Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., Teva
`Pharmaceutical Industries Ltd., Apotex, Inc., Apotex Corp.,
`Akorn, Inc., Mylan Pharmaceuticals Inc., and Mylan Inc., No.
`2:15-cv-01455
`
`Approved Drug Products with Therapeutic Equivalence
`Evaluations (34th Ed.) (2014) (Excerpts)
`
`File history of U.S. Patent No. 8,629,111 to Acheampong et al.
`(Exhibit Number Reserved in IPR2016-01128, -01129, -01130,
`& -01131)
`
`Complaint; Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., Teva
`Pharmaceutical Industries Ltd., Apotex, Inc., Apotex Corp.,
`Akorn, Inc., Mylan Pharmaceuticals Inc., No. 2:15-cv-01455
`(Exhibit Number Reserved in IPR2016-01128, -01129, -01130,
`& -01131)
`
`1026
`
`Reserved
`
`Allergan Department of Pharmacokinetics and Drug Metabolism
`Departmental Research Report, Report No: PK-00-163,
`Concentrations of Cyclosporin A in Cornea and Conjunctiva
`After a Single Ophthalmic Dose to New Zealand White Rabbits:
`Evaluation of 7 Ophthalmic Emulsion Formulations
`
`PROTECTIVE ORDER MATERIAL - Allergan R&D Records
`Management, Notebook Number L-2000-7626
`
`PROTECTIVE ORDER MATERIAL - Allergan R&D Records
`Management, Notebook Number L-1998-5709
`
`PROTECTIVE ORDER MATERIAL - Allergan R&D Records
`Management, Notebook Number L-1998-5707
`
`1027
`
`1028
`
`1029
`
`1030
`
`1031
`
`PROTECTIVE ORDER MATERIAL - Allergan R&D Records
`Management, Notebook Number L-2000-7726
`Orange Book 29th Edition (2009) (excerpts)
`1033 Mayssa Attar Professional Linkedin Profile
`
`1032
`
`-3-
`
`
`
`
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1038
`
`1039
`
`1040
`
`1041
`
`1042
`
`1043
`
`1044
`
`1045
`
`1046
`
`PROTECTIVE ORDER MATERIAL - Transcript of May 31, 2017
`Deposition of Robert S. Maness, Ph.D.
`
`PROTECTIVE ORDER MATERIAL - Transcript of June 1, 2017
`Deposition of Rhett Schiffman, M.D., M.S.Sc.
`
`PROTECTIVE ORDER MATERIAL - Transcript of June 7, 2017
`Deposition of Thorsteinn Loftsson, Ph.D.
`
`Transcript of June 20, 2017 Deposition of John D. Sheppard, M.D.,
`M.S.Sc.
`
`PROTECTIVE ORDER MATERIAL - Transcript of June 22, 2017
`Deposition of Mayssa Attar, Ph.D.
`
`REDACTED - Transcript of June 22, 2017 Deposition of Mayssa
`Attar, Ph.D.
`
`PROTECTIVE ORDER MATERIAL - Declaration of Andrew F.
`Calman, M.D.
`
`PROTECTIVE ORDER MATERIAL - Declaration of Daniel A.
`Bloch, Ph.D.
`
`PROTECTIVE ORDER MATERIAL - Declaration of Ivan T.
`Hofmann
`
`Curriculum Vitae of Andrew F. Calman, M.D.
`
`Curriculum Vitae of Daniel A. Bloch, Ph.D.
`
`Curriculum Vitae of Ivan T. Hofmann
`
`Facts About Dry Eye, NATIONAL EYE INSTITUTE OFFICE OF SCIENCE
`COMMUNICATIONS, PUBLIC LIAISON, AND EDUCATION, 2013,
`https://nei.nih.gov/health/dryeye/dryeye (accessed June 26,
`2017)
`
`Niederkorn, et al., Desiccating Stress Induces T Cell-Mediated
`Sjögren’s Syndrome-Like Lacrimal Keratoconjunctivitis, 176 J.
`IMMUNOL. 3950 (2006)
`
`-4-
`
`
`
`
`
`1047
`
`1048
`
`1049
`
`1050
`
`1051
`
`1052
`
`1053
`
`1054
`
`1055
`
`Garralt, S., Dry Eye Syndrome Preferred Practice Pattern,
`AMERICAN ACADEMY OF OPHTHALMOLOGY (2013)
`
`Garralt, S., Dry Eye Syndrome Preferred Practice Pattern Limited
`Revision, AMERICAN ACADEMY OF OPHTHALMOLOGY (2011)
`
`A real tear-jerker: Team creates device to alleviate dry eye,
`STANFORD MEDICINE NEWS CENTER,
`https://med.stanford.edu/news/all-news/2015/01/a- real-tear-
`jerker-team-creates-device-to-alleviate-dry-eye.html (accessed
`June 26, 2017)
`
`Allergan Granted Marketing Authorization by the FDA for
`TrueTearTM, the First Intranasal Neurostimulating Device
`Proven to Temporarily Increase Tear Production,
`https://www.allergan.com/News/News/Thomson-
`Reuters/Allergan-Granted-Marketing-Authorization-by-the-FD
`(accessed June 26, 2017)
`
`Dalton, M., Novel neurostimulator device uses nasal cavities to
`stimulate tears, OPHTHALMOLOGY TIMES,
`http://ophthalmologytimes.modernmedicine.com/ophthalmology
`times/news/novel- neurostimulator-device-uses-nasal-cavities-
`stimulate-tears?page=0,1 (accessed June 26, 2017)
`
`Marsh, P. and Pflugfelder S., Topical Nonpreserved
`Methylprednisolone Therapy for Keratoconjunctivitis Sicca in
`Sjörgen Syndrome, 106 OPHTHALMOL. 811 (1999)
`
`PubMed Abstract: Sainz de la Maza Serra, et al., Nonpreserved
`Topical Steroids and Punctal Occlusion for Severe
`Keratoconjunctivitis Sicca, 10 ARCH. SOC. ESP. OFTALMOL. 751
`(2000)
`
`Eadie, S., et al., Kerato-Conjunctivitis Sicca Treated With
`Cortisone and ACTH, 39 BRIT. J. OPHTHAL. 90 (1955)
`
`Gaulhofer, W. K., The Effect of Cortisone on Sjögren’s Syndrome,
`CXLIX, ACTA MEDICA SCANDINAVICA (1954)
`
`-5-
`
`
`
`
`
`1056
`
`1057
`
`1058
`
`1059
`
`1060
`
`1061
`
`1062
`
`Rolando, M., et al., Topical Non-Preserved Diclofenac Therapy for
`Keratoconjunctivitis Sicca, 506 ADV. EXP. MED. BIO.
`(LACRIMAL GLAND, TEAR FILM & DRY EYE SYNDROMES 3) 1237
`(2002)
`
`Glenn, C., New Thinking Spurs New Products, 1 REV.
`OPHTHALMOL. (FEB. 2003)
`
`Oellerich, et al., Lake Louise Consensus Conference on
`Cyclosporin Monitoring in Organ Transplantation: Report of
`the Consensus Panel, 17 THER. DRUG MONIT. 642 (1995)
`
`Foulks, G.N., et al., 2007 Report of the International Dry Eye
`Workshop (DEWS) 5 OCULAR SURF. 65 (2007)
`
`Avunduk, et al., The Comparison of Efficacies of Topical
`Corticosteroids and Nonsteroidal Anti-inflammatory Drops on
`Dry Eye Patients: A Clinical and Immunocytochemical Study,
`136 AM. J. OPHTHAL.593 (2003)
`
`Lamberts, D.W., Clinical Diseases of the Tear Film, THE CORNEA,
`3rd Ed., (eds. Smolin & Thoft (1994))
`Akpek, et al., Ocular Rosacea: Patient Characteristics and Follow-
`up, 104 OPHTHALMOL. 1863 (1997)
`
`1063
`
`Allergan Form 10-K for the year ended December 31, 2015
`
`1064
`
`FDA Approved Drug Products, New Drug Application No. 050790,
`DRUGS@FDA, https://www.accessdata.fda.gov/scripts/cder/daf
`/index.cfm?event=overview.process&ApplNo=050790
`(accessed June 20, 2017)
`
`1065
`
`Allergan Form 10-K for the year ended December 31, 2009
`
`-6-
`
`
`
`
`
`Allergan Introduces RESTASIS MULTIDOSE (Cyclosporine
`Ophthalmic Emulsion) 0.05 %, a New Delivery System for the
`One and Only FDA Approved Treatment to Help Patients
`Produce More of Their Own Tears, CISION PR NEWSWIRE,
`http://www.prnewswire.com/news-releases/allergan-introduces-
`restasis-multidose-cyclosporine-ophthalmic-emulsion-005-a-
`new-delivery-system-for-the-one-and-only-fda-approved-
`treatment-to-help-patients-produce-more-of-their-own-tears-
`300353429.html# (accessed June 20, 2017)
`
`FDA Label for Restasis MultiDose™
`
`Allergan Form 10-K for the year ended December 31, 1993
`
`Patent and Exclusivity for: N050790, ORANGE BOOK,
`https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm
`?Product_No=001&Appl_No=050790&Appl_type=N (accessed
`June 21, 2017)
`
`Kymionis, G.D., et al., Treatment of chronic dry eye: focus on
`cyclosporine, 2 CLIN. OPTHALMOL., 829 (2008)
`
`Chronic Dry Eye Disease, https://www.restasis.com/What-Is-
`Chronic-Dry-Eye-Disease (accessed June 21, 2017)
`
`1066
`
`1067
`
`1068
`
`1069
`
`1070
`
`1071
`
`1072
`
`Allergan Form 10-K for the year ended December 31, 2002
`
`1073
`
`1074
`
`1075
`
`Keratoconjunctivitis Sicca, MERCK MANUAL,
`http://www.merckmanuals.com/home/eye-disorders/corneal-
`disorders/keratoconjunctivitis-sicca (accessed June 21, 2017)
`
`Abelson and Smith, A Stepwise Approach to Acute Dry Eye,
`REVIEW OF OPHTHALMOLOGY,
`https://www.reviewofophthalmology.com/article/a-stepwise-
`approach-to-acute-dry-eye (accessed June 22, 2017)
`
`Javadi and Feizi, Dry Eye Syndrome, 6 J. OPHTHALMIC VIS. RES.
`192 (2011)
`
`1076
`
`Xiidra, https://www.xiidra.com/ (accessed June 22, 2017)
`
`-7-
`
`
`
`
`
`1077
`
`1078
`
`1079
`
`1080
`
`FDA approves new medication for dry eye disease, FDA NEWS
`RELEASE,
`http://www.fda.gov/NewsEvents/Newsroom/PressAnnounceme
`nts/ucm510720.htm (accessed June 22, 2017)
`
`Bailey, G., Shire gets FDA nod for Xiidra (lifitegrast) for dry eye,
`OPTOMETRY TIMES OPTOMETRY ALCON,
`http://optometrytimes.modernmedicine.com/optometrytimes/ne
`ws/shire-gets-fda-nod-xiidra-lifitegrast-dry-eye (accessed June
`22, 2017)
`
`Dry eyes, MAYO CLINIC, http://www.mayoclinic.org/diseases-
`conditions/dry-eyes/basics/treatment/con-20024129 (accessed
`June 22, 2017)
`
`Scleral Lenses, CONTACT LENS MANUFACTURERS ASSOCIATION,
`http://www.contactlenses.org/scleral.htm (accessed June 22,
`2017)
`
`1081
`
`Jedlicka, J., Scleral Contact Lenses, ALLABOUTVISION.COM,
`http://www.allaboutvision.com/contacts/scleral-lenses.htm
`(accessed June 22, 2017)
`1082 Merck & Co., Inc. v. Teva Pharms. USA, Inc., 395 F.3d 1364,
`1376-77 (Fed. Cir. 2005)
`
`1083
`
`1084
`
`1085
`
`1086
`
`New Patents Could Sustain Allergan Restasis Franchise Until
`2024, SEEKING ALPHA,
`http://seekingalpha.com/article/1945551-new-patents-could-
`sustain-allergan-restasis-franchise-until-2024 (accessed June 22,
`2017)
`FDA Label for Lacrisert®
`Stephenson, M., OTC Drops: Telling the Tears Apart, REV.
`OPHTHALMOL., https://www.reviewofophthalmology.com/
`article/otc-drops-telling-the-tears-apart (accessed June 20, 2017)
`
`Narayanan, S., Which Drop for Dry Eye?, REV. OPTOM., 2009,
`https://www.reviewofoptometry.com/article/which-drop-for-
`dry-eye (accessed June 20, 2017)
`
`-8-
`
`
`
`
`
`1087
`
`1088
`
`1089
`
`1090
`
`1091
`
`1092
`
`1093
`
`1094
`
`1095
`
`1096
`
`Schachet, J., The Golden Age of Dry Eye Management, REVIEW OF
`OPTOMETRY, 2008, https://www.reviewofoptometry.com/ce/the-
`golden-age-of-dry-eye-management (accessed June 20, 2017)
`
`Refresh Products, http://www.refreshbrand.com/Products (accessed
`June 23, 2017)
`
`Alrex (loteprednol etabonate ophthalmic suspension) 0.2%,
`BAUSCH + LOMB, http://www.bausch.com/ecp/our-products/rx-
`pharmaceuticals/rx-pharmaceuticals/alrex-loteprednol-
`etabonate-ophthalmic-suspension-02 (accessed June 23, 2017)
`
`Lotemax (loteprednol etabonate ophthalmic suspension) 0.5%,
`BAUSCH + LOMB, http://www.bausch.com/ecp/our-products/rx-
`pharmaceuticals/rx-pharmaceuticals/lotemax-ecp (accessed June
`23, 2017)
`
`Fluorometholone Suspension – Ophthalmic, MEDICINENET.COM,
`http://www.medicinenet.com/fluorometholone-
`ophthalmic_suspension/article.htm (accessed June 23, 2017)
`
`Rimexolone Suspension – Ophthalmic, MEDICINENET.COM,
`http://www.medicinenet.com/rimexolone-
`ophthalmic/article.htm (accessed June 23, 2017)
`
`Methylprednisolone (Oral Route), Mayo Clinic,
`http://www.mayoclinic.org/drugs-supplements/
`methylprednisolone-oral-route/description/drg-20075237
`(accessed June 23, 2017)
`
`Hessen, M. and Akpek, E., Dry Eye: an Inflammatory Ocular
`Disease, 9 J. OPHTHALMIC VIS. RES. 240 (2014)
`
`Dry Eye Syndrome, E MEDICINE HEALTH,
`http://www.emedicinehealth.com/dry_eye_syndrome-
`health/article_em.htm (accessed June 23, 2017)
`
`PubMed Abstract: Mrukwa-Kominek, et al., Effect of anti-
`inflammatory therapy on the treatment of dry eye syndrome, 109
`KLIN OCZNA 79 (2007)
`
`-9-
`
`
`
`
`
`1097
`
`1098
`
`1099
`
`1100
`
`1101
`
`1102
`
`1103
`
`1104
`
`1105
`
`1106
`
`1107
`
`1108
`
`1109
`
`1110
`
`Adler, R., Dry Eye Treatment: Getting Relief From Dry Eyes,
`ALLABOUTVISION.COM, http://www.allaboutvision.com/
`conditions/dryeye.htm (accessed June 23, 2017)
`
`Ramsey, L., How Allergan went from a tiny Los Angeles eye care
`company to the biggest takeover target of 2015, BUSINESS
`INSIDER, 2015, http://www.businessinsider.com/allergan-
`history-since-1948-founding-2015-11 (accessed June 22, 2017)
`
`Allergan Product Information,
`https://www.allerganoptometry.com/ Product-Information/
`(accessed June 23, 2017)
`
`Allergan Third Quarter 2016 Earnings Call Transcript
`
`Allergan Second Quarter 2016 Earnings Call Transcript
`
`Allergan Form 10-K for the year ended December 31, 2005
`
`Allergan Form 10-K for the year ended December 31, 2014
`
`Allergan Third Quarter 2015 Earnings Call Transcript
`
`Allergan Third Quarter 2013 Earnings Call Transcript
`
`Allergan Fourth Quarter 2007 Earnings Call Transcript
`
`Allergan First Quarter 2009 Earnings Call Transcript
`
`Allergan Third Quarter 2009 Earnings Call Transcript
`
`Weintraub, A., Allergan: Smoothing the Wrinkles,
`BLOOMBERG.COM, 2006,
`https://www.bloomberg.com/news/articles/2006-02-08/allergan-
`smoothing-the-wrinkles (accessed June 21, 2017)
`
`Restasis commercial among most memorable as of 2013, PMLIVE,
`http://www.pmlive.com/pharma_news/restasis_ad_among_most
`_memorable_of_2013_531999 (accessed June 21, 2017)
`
`-10-
`
`
`
`
`
`1111
`
`Actress Marisa Tomei Partners with Allergan to Raise Awareness
`of Chronis Dry Eye, CISION PR NEWSWIRE, 2016,
`http://www.prnewswire.com/news-releases/actress-marisa-
`tomei-partners-with-allergan-to-raise-awareness-of-chronic-dry-
`eye-300301221.html# (accessed on June 22, 2017)
`
`1112
`
`Allergan Form 10-K for the year ended December 31, 2011
`
`1113
`
`1114
`
`Bihari, M., Understanding Your Health Plan Drug Formulary,
`https://www.verywell.com/understanding-your-health-plan-
`drug-formulary-1738897 (accessed June 22, 2017)
`
`Copayment Tier Definitions, BLUE CROSS AND BLUE SHIELD OF
`NORTH CAROLINA, 2017,
`http://www.bcbsnc.com/content/services/ formulary/rxdef.htm
`(accessed June 22, 2017)
`
`1115
`
`Allergan Fourth Quarter 2015 Earnings Call Transcript
`
`1116
`
`1117
`
`The My Tears, My Rewards® Program Gives You Instant Savings
`on Every Prescription Plus Ongoing Support With Treatment,
`https://www.restasis.com/Savings-and-Support/Program-
`Benefits (accessed June 22, 2017)
`
`My Tears, My Rewards® Program Terms and Conditions,
`https://www.restasis.com/TermsOfUse/TermsAndConditions5
`(accessed June 22, 2017)
`
`1118
`
`List of testimony of Ivan T. Hofmann
`
`1119
`
`1120
`
`1121
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2012 U.S. Eye
`Care Sales & Marketing Plan: RESTASIS® Professional
`(AGN_RES1123159)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2006 U.S. Eye
`Care Sales & Marketing Plan: 2006 Optometric Business Plan
`(AGN_RES1147478)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2016 U.S. Eye
`Care Sales & Marketing Plan: Lifitegrast Plan and MDPF
`Overview (AGN_RES0614120)
`
`-11-
`
`
`
`
`
`1122
`
`Reserved
`
`1123
`
`1124
`
`1125
`
`1126
`
`1127
`
`1128
`
`1129
`
`1130
`
`1131
`
`1132
`
`1133
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2004 U.S.
`Managed Healthcare/Institutional/Government: Managed
`Healthcare RESTASIS® 2004 Strategies, “Paving the Way
`Through Managed Care” (AGN_RES1120941)
`PROTECTIVE ORDER MATERIAL – Allergan, RESTASIS®
`DTC Update, August 4, 2010 (AGN_RES1148612)
`
`PROTECTIVE ORDER MATERIAL – Natexis Bleichroeder Inc.,
`Allergan, Inc., First Call Note (AGN_RES0734285)
`
`PROTECTIVE ORDER MATERIAL – Bilal Ghazi 2007
`Marketing Plan (AGN_RES1124168)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2007 U.S. Eye
`Care Sales & Marketing Plan (AGN_RES1134471)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2009 U.S. Eye
`Care Sales & Marketing Plan: Strategic Communications/Phase
`IV (AGN_RES1146945)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2008 U.S. Eye
`Care Sales & Marketing Plan: Optometric Strategies Overview
`(AGN_RES1147652)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2016 Dry Eye
`Business Plan (AGN_RES1154033)
`
`PROTECTIVE ORDER MATERIAL – Allergan, 2008 U.S. Eye
`Care Sales & Marketing Plan: All Roads Lead to RESTASIS®
`(AGN_RES1153653)
`
`Schuurhuis, G. J., et al., The polyoxyethylene castor oil Cremophor
`EL modifies multidrug resistance, 62 MOT. J. CANCER, 591
`(1990)
`
`Declaration of Anna G. Phillips in support of Petitioner’s Motion
`for Pro Hav Vice Admission
`
`1134
`
`June 5, 2017 Email Regarding Deposition Requests
`
`-12-
`
`
`
`
`
`1135
`
`July 6, 2017 Email Regarding Patent Owner’s Sur-reply
`
`1136
`
`1137
`
`1138
`
`1139
`
`1140
`
`1141
`
`
`1142
`
`1143
`
`1144
`
`1145
`
`July 21, 2017 Email Regarding New Arguments and Evidence in
`Patent Owner’s Sur-reply
`
`Transcript of Telephonic Hearing Held Monday, 11 September
`2017, in IPR2016-01127; IPR2016-01128; IPR2016-01129;
`IPR2016- 01130; IPR2016-01131 and IPR2016-01132
`
`Declaration of Shannon M. Bloodworth in support of Petitioner’s
`Motion for Pro Hac Vice Admission
`
`Declaration of Charles G. Curtis, Jr. in support of Petitioner’s
`Motion for Pro Hac Vice Admission
`
`Declaration of Jennifer A. MacLean in support of Petitioner’s
`Motion for Pro Hac Vice Admission
`
`Declaration of Eric D. Miller in support of Petitioner’s Motion for
`Pro Hac Vice Admission
`
`Declaration of Benjamin S. Sharp in support of Petitioner’s Motion
`for Pro Hac Vice Admission
`
`Transcript of Telephonic Hearing Held Tuesday, 26 September
`2017, in IPR2016-01127; IPR2016-01128; IPR2016-01129;
`IPR2016- 01130; IPR2016-01131 and IPR2016-01132
`
`Partnership Between Drug Giant and Native American Tribe May
`Affect Patent Challenges,
`http://www.npr.org/templates/transcript/transcript.php?storyId=
`552181878 (accessed October 13, 2017)
`
`Frequently Asked Questions about New Research and Technology
`(Patent) Business, https://www.srmt-
`nsn.gov/_uploads/site_files/Office-of-Technology-Research-
`and-Patents-FAQs.pdf (accessed October 13, 2017) downloaded
`from EX1157
`
`-13-
`
`
`
`
`
`1146
`
`1147
`
`
`1148
`
`Allergan’s patent transaction with St. Regis Mohawks could
`presage more arbitrage patent transactions, IPWATCHDOG,
`http://www.ipwatchdog.com/2017/09/18/allergans-patent-
`transaction-with-st-regis-mohawks-could-presage-more-
`arbitrage-patent-transactions/id=87970 (accessed October 13,
`2017)
`
`Sovereign immunity protects patent owners from what some see as
`PTAB's kangaroo court, says tribe lawyer, IAM-MEDIA.COM,
`http://www.iam-media.com/Blog/Detail.aspx?g=e6d0e737-
`a215-484e-989f-a7c791c901ef (accessed October 13, 2017)
`
`Allergan Partners With Indian Tribe to Protect Drug Patents -- 3rd
`Update, FOX BUSINESS,
`http://www.foxbusiness.com/features/2017/09/08/allergan-
`partners-with-indian-tribe-to-protect-drug-patents-3rd-
`update.html (accessed October 13, 2017)
`
`1149
`
`Health-Care Alliances Letter to Congress, October 10, 2017
`
`1150
`
`1151
`
`1152
`
`Waxman hits out at Allergan patent deal with Mohawk tribe,
`FINANCIAL TIMES, https://www.ft.com/content/81bd8930-abb8-
`11e7-aab9-abaa44b1e130?mhq5j=e7 (accessed October 13,
`2017)
`
`Plaintiff’s Production of Documents in Response to Court’s
`October 6, 2017 Order, Case No. 2:15-cv-01455-WCB, D.I.
`510, Filed 10/10/17
`
`Jay, W. M., Santos, J.A., Patent-Assignment Transactions Between
`Brand-Name Drug Companies and Native American Tribes Will
`Undermine a Healthy Patent System and Harm Patients, AAM
`WHITE PAPER, October 12, 2017,
`https://www.accessiblemeds.org/sites/default/files/2017-
`10/AAM%20White%20Paper%20Renting%20Tribal%20Immu
`nity%20to%20Evade%20IPR%20Review%20of%20Pharmaceu
`tical%20Patents.pdf (accessed October 13, 2017 from
`https://www.accessiblemeds.org/)
`
`-14-
`
`
`
`1153
`
`1154
`
`1155
`
`1156
`
`1157
`
`1158
`
`1159
`
`1160
`
`1161
`
`
`
`Allergan pays Mohawk Tribe to protect patents from challenges,
`REUTERS, https://www.reuters.com/article/us-allergan-patents-
`mohawk/allergan-pays-mohawk-tribe-to-protect-patents-from-
`challenges-idUSKCN1BJ2DK (accessed October 13, 2017)
`
`Plaintiff Allergan, Inc.’s Response to Defendants’ Motion for
`Summary Judgment of Non-Infringement, Case No. 2:15-cv-
`01455-WCB, D.I. 460, Filed 8/22/17 (Public Version),
`Excerpted
`
`A Native American Tribe, a Drugmaker and an Unusual Patent
`Plan, BLOOMBERG NEWS,
`https://www.bloomberg.com/news/articles/2017-09-08/allergan-
`makes-deal-with-native-american-tribe-over-drug-patents
`(accessed October 13, 2017)
`
`Brief for the Federal Respondent in Opposition, Oil States Energy
`Services LLC v. Greene’s Energy Group, LLC, No. 16-712
`(U.S. Apr. 28, 2017), downloaded from
`https://www.justice.gov/sites/default/files/briefs/2017/05/01/16-
`712_oil_states_energy_servs._llc_opp.pdf (accessed October
`13, 2017)
`
`Allergan and Saint Regis Mohawk Tribe Announce Agreements
`Regarding RESTASIS® Patents, https://www.srmt-
`nsn.gov/news/2017/allergan-and-saint-regis-mohawk-tribe-
`announce-agreements-regarding-restasis-patents (accessed
`October 13, 2017)
`
`FlowRider Surf, Ltd. v. Pac. Surf Designs, Inc., 2017 WL 2349031
`(S.D. Cal. May 26, 2017)
`
`Gingras v. Rosette, Case No. 5:15-cv-101, 2016 WL 2932163 (D.
`Vt. May 18, 2016)
`
`Commonwealth v. Think Finance, Inc., No. 14-cv-7139, 2016 WL
`183289 (E.D. Pa. Jan. 14, 2016)
`
`SourceOne Global Partners, LLC v. KGK Synergize, Inc., No. 08-
`C-7403, 2009 WL 1346250 (N.D. Ill. May 13, 2009)
`
`-15-
`
`
`
`
`
`1162
`
`1163
`
`1164
`
`1165
`
`Diné Citizens Against Ruining Our Env’t. v. U.S. Office of Surface
`Mining Reclamation & Enf’t, No. 12-cv-1275-AP, 2013 WL
`68701 (D. Colo. Jan. 4, 2013)
`
`Memorandum Opinion and Order, Docket No. 522; Allergan, Inc.,
`and The Saint Regis Mohawk Tribe v. Teva Pharmaceuticals
`USA, Inc., Mylan Inc., Mylan Pharmaceuticals Inc., and Akorn,
`Inc., No. 2:15-cv-01455-WCB (October 16, 2017)
`
`Findings of Fact and Conclusions of Law, Docket No. 523;
`Allergan, Inc., and The Saint Regis Mohawk Tribe v. Teva
`Pharmaceuticals USA, Inc., Mylan Inc., Mylan Pharmaceuticals
`Inc., and Akorn, Inc., No. 2:15-cv-01455-WCB (October 16,
`2017)
`
`Final Judgment, Docket No. 524; Allergan, Inc., and The Saint
`Regis Mohawk Tribe v. Teva Pharmaceuticals USA, Inc., Mylan
`Inc., Mylan Pharmaceuticals Inc., and Akorn, Inc., No. 2:15-cv-
`01455-WCB (October 16, 2017)
`
`1166
`
`October 11, 2017 Email Chain
`
`1167
`
`Brief for the Federal Respondent, Oil States Energy Services, LLC,
`v. Greene’s Energy Group, LLC, et al., No. 16-712, October
`2017.
`
`1168
`
`Transcript of Telephonic Hearing Held Monday, 05 March 2018, in
`IPR2016-01127; IPR2016-01128; IPR2016-01129; IPR2016-
`01130; IPR2016-01131 and IPR2016-01132
`1169 Wright et al., Federal Practice & Proc. Juris. § 3914.10 n. 71 (2d
`ed.) (excerpts)
`
`1170 Wright et al., Federal Practice & Proc. Juris. § 3914.18 (2d ed.)
`
`1171
`
`H.R. REP. 112-98, 45-48 (2011) (excerpts)
`
`1172
`
`Judgment, Allergan, Inc., and The Saint Regis Mohawk Tribe v.
`Teva Pharmaceuticals USA, Inc., Akorn, Inc., Mylan
`Pharmaceuticals Inc., and Mylan Inc., No. 2018-1130 (CAFC –
`November 13, 2018)
`
`-16-
`
`
`
`
`
`1173
`
`1174
`
`Transcript of August 1, 2017 Pretrial Hearing, Case No. 2:15-cv-
`014455-WCB (excerpts)
`
`Transcript of Telephonic Hearing Held Thursday, 13 December
`2018, in IPR2016-01127; IPR2016-01128; IPR2016-01129;
`IPR2016- 01130; IPR2016-01131 and IPR2016-01132
`
`-17-
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`This is to certify that I caused to be served true and correct copies of the
`
`foregoing Petitioners’ Updated Exhibit List and Exhibit 1174 on this 2nd day of
`
`January 2019, on Allergan, Inc. and the St. Regis Mohawk Tribe as follows:
`
`Dorothy P. Whelan
`Michael Kane
`Susan Morrison Colletti
`Robert M. Oakes
`Jonathan Singer
`Fish & Richardson P.C.
`Email: IPR13351-0008IP1@fr.com
`Email: IPR13351-0008IP2@fr.com
`Email: IPR13351-0008IP3@fr.com
`Email: IPR13351-0008IP4@fr.com
`Email: IPR13351-0008IP5@fr.com
`Email: IPR13351-0008IP6@fr.com
`Email: PTABInbound@fr.com
`
`Alfonso Chan
`Joseph DePumpo
`Michael W. Shore
`Christopher L. Evans
`Shore Chan DePumpo LLP
`Email: achan@shorechan.com
`Email: jdepumpo@shorechan.com
`Email: mshore@shorechan.com
`Email: cevans@shorechan.com
`
`Marsha K. Schmidt
`Email: marsha@mkschmidtlaw.com
`
`
`
`-18-
`
`
`
`And on the remaining Petitioners as follows:
`
`
`
`Gary Speier
`Mark Schuman
`Ralph Wilson Powers III
`Carlson, Caspers, Vandenburgh,
`Lindquist & Schuman, P.A.
`Email: gspeier@carlsoncaspers.com
`Email: mschuman@carlsoncaspers.com
`Email: tpowers-PTAB@sternkessler.com
`Email: IPRCyclosporine@carlsoncaspers.com
`Email: PTAB@sternkessler.com
`Attorneys for Teva Pharmaceuticals USA, Inc.
`
`Michael Dzwonczyk
`Mark Boland
`Email: mdzwonczyk@sughrue.com
`Email: mboland@sughrue.com
`Attorneys for Akorn Inc.
`
`
`
`
`
`
`
`
`
`Dated: January 2, 2019
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
`Steven W. Parmelee, Lead Counsel
`Reg. No. 31,990
`
`
`
`-19-
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
